Tag #Boehringer Ingelheim

Showing 1 to 3 of 3 results

welt.de

🌐 75% Global Worthiness

Jul 25, 07:13

Rhineland-Palatinate Climate Law Sparks Industry Concerns

Boehringer Ingelheim, along with other major companies like BASF and Schott, expressed concerns about Rhineland-Palatinate's new climate law, which mandates carbon neutrality by 2040—five years earlier than the federal target—raising fears of industrial competitiveness issues and potential job losse...

Rhineland-Palatinate Climate Law Sparks Industry Concerns

Boehringer Ingelheim, along with other major companies like BASF and Schott, expressed concerns about Rhineland-Palatinate's new climate law, which mandates carbon neutrality by 2040—five years earlier than the federal target—raising fears of industrial competitiveness issues and potential job losse...

Progress

56% Bias Score

ShareSaveArticle

Climate Action

12345678

Previous 1 of 8 Next

What are the immediate economic implications for energy-intensive industries in Rhineland-Palatinate due to the state's accelerated climate neutrality target?

Boehringer Ingelheim, while committed to its 2030 carbon neutrality goal for production, expresses reservations about Rhineland-Palatinate's accelerated 2040 climate neutrality target. This faster timeline, set by the state's new climate protection law, raises concerns about competitiveness and potential job losses within the industry. The company, while largely self-sufficient in green energy at its Ingelheim site, relies on external suppliers, highlighting the interconnectedness of the issue.

zeit.de

🌐 75% Global Worthiness

Apr 2, 16:09

Boehringer Ingelheim's 2024 Revenue Up 6.1%, Faces US Tariff, Regulatory Challenges

Boehringer Ingelheim reported a 6.1% increase in 2024 revenue (€26.8 billion), driven by strong sales of Jardiance and Nexgard, while investing €6.2 billion in R&D and facing potential US tariff impacts and regulatory hurdles in Germany.

Boehringer Ingelheim's 2024 Revenue Up 6.1%, Faces US Tariff, Regulatory Challenges

Boehringer Ingelheim reported a 6.1% increase in 2024 revenue (€26.8 billion), driven by strong sales of Jardiance and Nexgard, while investing €6.2 billion in R&D and facing potential US tariff impacts and regulatory hurdles in Germany.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How is Boehringer Ingelheim addressing the challenges posed by potential US tariffs and regulatory delays in Germany?

Boehringer Ingelheim's success stems from its key products' growth and substantial R&D investment. Regionalizing supply chains, as exemplified by Jardiance's US production, mitigates risks. However, future US tariffs and potential delays in German drug approvals (Zongertinib) pose challenges.

welt.de

🌐 75% Global Worthiness

Apr 2, 16:09

Boehringer Ingelheim's 2024 Sales Surge Driven by Jardiance, but US Pricing and EU Regulations Pose Challenges

Boehringer Ingelheim reported €21.9 billion in human pharmaceutical sales in 2024, a 7% increase year-over-year, driven by Jardiance (€8.4 billion), while animal health sales reached €4.7 billion, with Nexgard (€1.35 billion) leading the growth; the company invested €6.2 billion in R&D and anticipat...

Boehringer Ingelheim's 2024 Sales Surge Driven by Jardiance, but US Pricing and EU Regulations Pose Challenges

Boehringer Ingelheim reported €21.9 billion in human pharmaceutical sales in 2024, a 7% increase year-over-year, driven by Jardiance (€8.4 billion), while animal health sales reached €4.7 billion, with Nexgard (€1.35 billion) leading the growth; the company invested €6.2 billion in R&D and anticipat...

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What were the key financial results for Boehringer Ingelheim in 2024, and what factors drove this performance?

Boehringer Ingelheim reported a 7% increase in human pharmaceutical sales to €21.9 billion in 2024, driven by a 14%+ surge in Jardiance sales to €8.4 billion. Animal health sales also grew by 1.9% to €4.7 billion, with Nexgard sales increasing by 14% to €1.35 billion. The company invested €6.2 billion in R&D, anticipating several new product launches, potentially two in 2025.

Showing 1 to 3 of 3 results